Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Midazolam increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via the miR-194-5p/HOOK3 axis

Fig. 3

Midazolam upregulated miR-194-5p to improve cisplatin-sensitivity in CR-NSCLC cells. A, B The A549/DDP cells and H1299/DDP cells were stimulated with midazolam for 24 h, and Real-Time qPCR was performed to examine the expression levels of the eight cisplatin-resistance associated miRNAs, which were shown by using the heat map. The expression levels of miR-194-5p in CS-NSCLC and CR-NSCLC C cells and D clinical tissues were measured by performing the Real-Time qPCR analysis. E, F The miR-194-5p mimic and inhibitor were respectively transfected into the CR-NSCLC cells, and the transfection efficiency was determined. G, H MTT assay and (I, J) trypan blue staining assay were conducted to investigate the effects of cisplatin, midazolam and miR-194-5p inhibitor on cell proliferation and viability. KM Cell apoptosis in the A549/DDP and H1299/DDP cells was determined by FCM. Individual experiment contained at least 3 repetitions, and *P < 0.05, **P < 0.01, and ***P < 0.001 was considered as statistical significance

Back to article page